Navigation Links
NVHR Offers Congressman Hank Johnson Support & Encouragement as He Battles Chronic Hepatitis C Virus
Date:12/7/2009

WASHINGTON, Dec. 7 /PRNewswire-USNewswire/ -- With today's forthright and valiant announcement by Congressman Hank Johnson (D-Ga.) that he is undergoing treatment for chronic hepatitis C virus, the National Viral Hepatitis Roundtable (NVHR) wishes to offer Congressman Johnson, Mrs. Johnson, and his entire family and staff our unwavering support as he works towards a cure.

Congressman Hank Johnson is believed to be the first sitting Member of Congress to acknowledge he is afflicted with chronic hepatitis C virus.

The NVHR is a coalition of more than 150 public, private, and voluntary organizations dedicated to reducing the incidence of infection, morbidity, and mortality from viral hepatitis in the U.S. through strategic planning, leadership, coordination, advocacy, and research. www.nvhr.org

"NVHR and the entire viral hepatitis community offer Congressman Johnson our support and encouragement as he battles chronic hepatitis C virus," said NVHR Chair Lorren Sandt. "In choosing to disclose his condition, Congressman Johnson is helping to propel chronic viral hepatitis to the forefront of our nation's public-health agenda. We are hopeful that Congressman Johnson's announcement will help spur greater awareness about the need for increased prevention, detection, and treatment of chronic viral hepatitis B and C."

In light of this announcement, the NVHR encourages the American people to use it as an opportunity to learn more about the need to address the urgent public health crisis of chronic viral hepatitis B and C infection and to recognize that viral hepatitis is treatable. Hepatitis B is well managed with medications and more than 50 percent of hepatitis C patients are cured with anti-viral therapies. Bipartisan legislation was recently introduced in Congress by Representative Mike Honda (D-Calif.) and Charles Dent (R-Pa.) that would increase federal funding for comprehensive prevention, research, and medical management referral programs for chronic viral hepatitis B and C infection.

An estimated 5.4 million Americans - roughly 1 in 50 - are afflicted with chronic viral hepatitis infection and most don't even know it. Left undetected and untreated, chronic hepatitis B and C can lead to cirrhosis, liver cancer, or liver failure. While African Americans and Asian Americans are disproportionately afflicted with chronic viral hepatitis infection, the diseases infect all walks of life in American society.

In January 2010, the Institute of Medicine (IoM) is expected to release a report on viral hepatitis in the United States that outlines strategies for reducing the incidence of viral hepatitis infection and to mitigate complications in those individuals with chronic infections.

SOURCE National Viral Hepatitis Roundtable


'/>"/>
SOURCE National Viral Hepatitis Roundtable
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Health care incentive model offers collaborative approach
2. Eye-staining technique offers early detection for dry eye syndrome
3. Governor Rendell Offers adultBasic Coverage to 35,000 Uninsured Pennsylvanians
4. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
5. Psoriasis Cure Now offers Back to School Resources for Parents of Children with Psoriasis
6. ADDAS Awareness Campaign Offers Resources and Education to Adults Living with AD/HD and Professionals Working With Them
7. Regence Offers InterM to Fill Gap for the Uninsured
8. National Non-Profit Organization Offers Free Mental Health Services to Military and Military Families
9. Blue Cross Blue Shield of Michigan Offers New Approach to Customer Group Wellness
10. ProAssurance Group Offers Coverage for Community Based Hospitals in Michigan
11. Super Jake Foundation Offers Hope for Pediatric Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... Usually, the impending arrival of ... However, for those self-conscious about a double chin, this means more anxiety than elation. ... , “For most people, a double chin is undesirable,” Dr. Goldman said, “but ...
(Date:3/28/2017)... ... March 28, 2017 , ... Award-winning medical group Allied ... as new board chair for Orange County health care system CalOptima Friday. CalOptima ... soon-to-be former chair Mark Refowitz’s term, which runs through June 30 of this ...
(Date:3/28/2017)... ... , ... With less than 10,000 dermatologists in the United States and more ... while the desire to conquer breakouts and eliminate skincare stress is widespread. Curology ... today released its inaugural survey on the State of Acne in America. , ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... The Executives, ... to raise money to for the Toys for Tots Literacy Campaign at their Semi-Annual ... in excess of $70 billion, the U.S. ranks at number 14 internationally in literacy. ...
(Date:3/28/2017)... CA (PRWEB) , ... March 28, 2017 , ... ... which will be offered by the American Association of Integrative Medicine and available ... for healthcare providers at the AutismOne 2017 Conference in Colorado Springs. , Ed ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017  Market leading ... announced a partnership with premium news content provider ... companies to extract key insights from Dow Jones ... technology. The Linguamatics I2E platform is ... global pharmaceutical companies. The Linguamatics-Dow Jones partnership helps ...
(Date:3/28/2017)... Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today ... Christopher Gabrieli , partner emeritus ... of the board of Akcea Therapeutics. ... Sandford D. Smith , founder and ... are excited to announce this expansion to our board and ...
(Date:3/28/2017)... 28, 2017 RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Japan Patent Office (JPO) for the composition of ... (CTGF) for the treatment or prevention of fibrotic ... and proliferative retinopathy (Japanese Patent #: 6060071).  This ...
Breaking Medicine Technology: